Efficacy of intravenous thrombolysis in treating cortical and lacunar strokes: analysis from the Qatar Stroke Registry in a multi-ethnic population Authors: Kim H Tran, Naveed Akhtar, Sujatha Joseph, Deborah Morgan, Blessy Babu, Ryan Uy, Ashfaq Shuaib Published: 2025 ABSTRACT AbstractObjectiveIntravenous thrombolysis is an effective method in treating acute ischaemic stroke, with several studies reporting improved outcomes and reduced mortality rates. However, there are limited data on whether thrombolysis is effective in treating different ischaemic stroke subtypes in the Middle East and North African region.MethodsData of cortical and lacunar patients who received intravenous thrombolysis from the Qatar Stroke Registry were retrospectively analysed from April 2014 to January 2025. Patients were matched 1:2 for age and admission National Institute of Health Stroke Scale (NIHSS).ResultsPatients with cortical stroke who received recombinant tissue-type plasminogen activator (rt-PA) had a significantly lower proportion of a poor clinical outcome at 90 days (modified Rankin Scale (mRS) score of 3–6; 41.5% vs 50.5%, p=0.002), significantly lower NIHSS score at discharge (NIHSS score >10: 23.0% vs 33.9%, p<0.001), significantly lower proportion of mortality at 90 days (4.7% vs 8.2%, p=0.02) and significantly shorter length of stay (5.2 days vs 6.0 days, p=0.01) compared with controls. In terms of outcomes for patients with lacunar stroke, there were no significant differences compared with controls for their mRS score at 90 days (p=0.054), NIHSS score at discharge (p=0.21), mortality at 90 days (p=0.67) and length of stay (p=0.34). A multivariate conditional logistic regression model revealed that high admission NIHSS score (>10) was a significant predictor of a poor functional outcome at 90 days for cortical stroke post rt-PA (p<0.001), whereas for lacunar stroke, both high admission NIHSS score (>10) and symptom onset of >3 hours were identified as significant predictors of a poor functional outcome at 90 days post rt-PA (p=0.01 for both). History of diabetes mellitus and hypertension were also significant predictors of poor clinical outcome at 90 days, but this was only observed for cortical stroke (p<0.001 and p=0.003).ConclusionIn this study, intravenous thrombolysis yielded significant clinical outcomes for patients with cortical stroke but not patients with lacunar stroke.Keywords: STROKE WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS This study is the first to compare stroke outcomes post-intravenous thrombolysis therapy in a multi-ethnic population in the MENA region. We found that patients with cortical stroke who received alteplase had a lower proportion of mortality at 90 days, lower proportion of poor functional outcome at 90 days, shorter length of stay and lower NIHSS score at discharge. Conversely, intravenous thrombolysis yielded no benefits for patients with lacunar stroke. This study is the first to compare stroke outcomes post-intravenous thrombolysis therapy in a multi-ethnic population in the MENA region. We found that patients with cortical stroke who received alteplase had a lower proportion of mortality at 90 days, lower proportion of poor functional outcome at 90 days, shorter length of stay and lower NIHSS score at discharge. Conversely, intravenous thrombolysis yielded no benefits for patients with lacunar stroke. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Our results suggest that for patients with lacunar stroke, intravenous thrombolysis did not yield significant benefits compared with patients with cortical stroke. Our results suggest that for patients with lacunar stroke, intravenous thrombolysis did not yield significant benefits compared with patients with cortical stroke. Introduction Lacunar stroke subtype accounts for approximately 25% of all ischaemic stroke while cardioembolic stroke and large artery atherosclerosis (LAA)/large vessel disease, which are major subtypes of cortical strokes, account for 20–30% and 10–20% of strokes.1 2 Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) is recommended for acute ischaemic stroke treatment regardless of stroke subtype, with earlier initiation of treatment resulting in better long-term functional outcomes.3,6 However, the efficacy of rt-PA in treating lacunar stroke remains to be contested because its pathogenetic mechanism (lipohyalinosis and microatheroma) might not be susceptible to the thrombolytic effects of rt-PA.7,10 In contrast, rt-PA has been shown to be effective in treating cortical strokes.11 In the Middle East and North African (MENA) region, there are approximately 7.3 million cases of stroke reported annually, with 300 000 deaths reported in 2019.12 Previous rt-PA stroke studies in the MENA region have only analysed functional outcomes of patients with acute ischaemic stroke based on their ethnicity and treatment strategy instead of stroke subtype.13 Therefore, the purpose of this study is to determine the outcome of patients with acute ischaemic stroke receiving rt-PA based on their stroke subtype (lacunar vs cortical stroke) in the MENA region. Methods We retrospectively analysed all patients with stroke treated with intravenous rt-PA in our centre from January 2014 to January 2025. Patients were divided into two groups prior to treatment: those with a lacunar stroke and those with a cortical stroke (large vessel disease and/or cardioembolic stroke). Patient characteristics Patient characteristics including age, sex, nationality, medical comorbidities and prior medication were collected in the Stroke Registry. Data from the National Institute of Health Stroke Scale (NIHSS) score, neuroimaging data and post-discharge disposition were entered into the registry. Ischaemic stroke was diagnosed according to the WHO criteria and stroke subtypes by the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria (please see our previous studies for stroke and medical comorbidities classification).14 15 The modified Rankin Scale (mRS) measurements were done at discharge and at 90 days following onset of symptoms. The patients were classified as favourable (mRS ≤0–2) or unfavourable (mRS 3–6) outcome. Diabetes was diagnosed according to the American Diabetes Association (ADA) and WHO recommendation and included patients with a previous diagnosis of diabetes, on medication for diabetes or a hemoglobin A1C (HbA1c) of equal to or greater than 6.5%, and the diagnosis of pre-diabetes was based on an HbA1c of 5.7–6.4% as per the 2015 ADA clinical practice recommendations. Hypertension was defined as systolic blood pressure (BP) ≥140 mm Hg or a diastolic pressure ≥90 mm Hg, or on current treatment with antihypertensive drugs. Dyslipidaemia was defined as low-density lipoprotein cholesterol (LDL-C) level ≥3.62 mmol/L, high-density lipoprotein cholesterol (HDL-C) level ≤1.03 mmol/L, triglycerides ≥1.69 mmol/L or current treatment with a cholesterol-lowering drug. Each patient in the lacunar stroke group was matched with two patients in the non-lacunar stroke group according to their age and NIHSS admission score. The same method was applied for patients with cortical stroke. The NIHSS and mRS were recorded prospectively via the stroke nurse navigators in all cases. Intravenous alteplase was given to patients with cortical and lacunar stroke who required intravenous thrombolysis. Lacunar and cortical strokes were defined by a combination of clinical features and radiological information (the infarct location on CT/MRI). Data collection Upon identification and confirmation of diagnosis using the International Classification of Disease, 10th edition, definitions (H34.1, I63.x, I64.x, I61.x, I60.x, G45.x), patients’ data were collected by trained stroke coordinators. The ethnicities of the patients were recorded at admission. Computed tomography/Computed tomography angiography (CT/CTA) and computed tomography perfusion (CTP) were done in most patients. MRI was obtained in more than 60% of cases. We recorded the location of the stroke or intracerebral hemorrhage (ICH). The data on the severity of carotid disease or changes on the CTP were however not recorded in the registry. The data were prospectively collected by specialised nurse navigators who entered the data in the stroke registry on a daily basis. Following discharge, the patients were either seen in the stroke prevention clinic at 90 days or phoned for their mRS and other clinical follow-ups. Some expatriate patients would leave Qatar following their stroke. Attempts were made to phone them in their home country. For most patients, we were able to make contact and obtain the information; however, there were occasional cases where we were unable to contact them. As the information was collected prospectively, there are very little missing data during the hospital course for the patients. Informed consent was waived from participants in the study due to its retrospective nature. The project was approved by the Institutional Review Board of Hamad Medical Corporation in full compliance with national legislation and institutional requirements. Data analysis and statistics Descriptive results for all continuous variables were reported as mean±SD for normally distributed data (using independent samples’ t-test) or median with range for data with non-normal distributions (using Mann-Whitney U-test). Mean level comparisons between patients treated with rt-PA versus without were assessed using analysis of variance (ANOVA) test and multiple comparisons were performed using Bonferroni correction. If an assumption of an ANOVA test was failed, then an alternative non-parametric Kruskal-Wallis test was performed. Pearson’s χ2 test and Fisher’s exact test were performed whenever appropriate to compare the proportion of all categorical variables between the groups. A 1:2 ratio of one case to two controls, matched by age and admission NIHSS score, was used. We performed multivariable conditional logistic regression models of matched observations to identify the independent predictors of a higher mRS at 90 days (3–6) following thrombolysis with rt-PA. Since we had <5 patients with a symptom onset of >4.5 hours, we included them in the >3 hours category for multivariate conditional logistic regression analysis to reach convergence. Results of regression models were reported using ORs and 95% CIs. A p value of ≤0.05 (two-tailed) was considered significant. Results In our cohort, there were 4424 patients with lacunar stroke, 270 received rt-PA and 4154 did not receive rt-PA. In contrast, there were 3854 patients with cortical stroke (large vessel disease and cardioembolic stroke combined), of which 631 received rt-PA and 3223 did not. After matching our patients in a 1:2 ratio based on age and admission NIHSS, there were 229 patients with lacunar stroke who received rt-PA vs 475 controls, and 466 patients with cortical stroke who received rt-PA versus 992 controls. Symptomatic haemorrhage was defined by the SITS-MOST criteria (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) as local or remote parenchymal haemorrhage on the 22–36-hour post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 hours, or leading to death. The rate of symptomatic ICH post-TPA was 1.7% and 2.1% for patients with lacunar and patients with cortical stroke, respectively. For patients with cortical stroke, there were no significant differences in baseline characteristics between patients who received rt-PA versus controls: age (p=0.80), sex (p=0.17), serum HDL-C (p=0.40), serum LDL-C (p=0.60), serum triglyceride levels (p=0.19), hypertension (p=0.91), hypercholesterolaemia (p=0.13), atrial fibrillation (p=0.29) and smoking status (p=0.70). However, there was a significant difference between groups for onset of symptoms (p<0.001) and NIHSS score at admission (p=0.03) (see table 1). Patients with cortical stroke who received rt-PA had a significantly lower proportion of a high mRS score (3–6) at 90 days (41.5% vs 50.5%, p=0.002), significantly lower NIHSS score at discharge (NIHSS score >10: 23.0% vs 33.9%, p<0.001), significantly lower proportion of mortality at 90 days (4.7% vs 8.2%, p=0.02) and significantly lower length of stay at the hospital (5.2 days vs 6.0 days, p=0.01) compared with patients with cortical stroke who did not receive rt-PA. Table 1Demographic and patient outcomes in patients with cortical stroke who received thrombolysis and those without thrombolysis using a 1:2 matching processGroupCortical stroke non-lysisCortical stroke lysisP valueN992466Age (median, IQR)54.0 (45.0–63.0)54.0 (45.0–63.0)0.80Male sex, n (%)773 (77.9)378 (81.1)0.17Serum HbA1C levels (median, IQR)6.60 (5.8–9.2)6.20 (5.6–8.2)<0.001Serum HDL-C (median, IQR)1.0 (0.8–1.2)1.0 (0.8–1.2)0.40Serum LDL-C (median, IQR)3.0 (2.2–3.8)3.0 (2.2–3.7)0.60Serum triglyceride levels (median, IQR)1.4 (1.0–1.9)1.4 (1.0–2.0)0.19Onset of symptoms<0.001 <1.5 hours79 (9.7)177 (38.3) 1.5–3 hours94 (11.5)204 (44.2) 3–4.5 hours101 (12.4)77 (16.7) >4.5 hours542 (66.4)4 (0.9)mRS at 90 days0.002 0–2, n (%)467 (49.5)255 (58.5) 3–6, n (%)477 (50.5)181 (41.5)NIHSS score at admission0.03 0–4210 (21.2)80 (17.2) 5–10389 (39.2)216 (46.5) >10393 (39.6)169 (36.3)NIHSS score at discharge<0.001 0–4282 (37.1)224 (54.8) 5–10220 (28.9)91 (22.2) >10258 (33.9)94 (23.0)Mortality at 90 days, n (%)0.02 Yes, n (%)81 (8.2)22 (4.7) No, n (%)911 (91.8)444 (95.3)Risk factors Hypertension, n (%)660 (66.5)308 (66.1)0.91 Diabetes, n (%)593 (59.8)232 (49.8)<0.001 Hypercholesterolaemia, n (%)423 (42.6)219 (47.0)0.13 Prior stroke, n (%)82 (8.3)16 (3.4)<0.001 Atrial fibrillation, n (%)101 (22.1)40 (20.7)0.76 Smoking, n (%)227 (22.9)111 (23.8)0.70 Length of stay, median (IQR)6.0 (3.6–11.0)5.2 (3.3–8.9)0.01HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale. Demographic and patient outcomes in patients with cortical stroke who received thrombolysis and those without thrombolysis using a 1:2 matching process HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale. For patients with lacunar stroke, there were no significant differences in baseline characteristics between patients who received rt-PA versus controls: age (p=0.84), sex (p=0.29), serum HbA1C (p=0.58), serum HDL-C (p=0.64), serum LDL-C (p=0.92), diabetes (p=0.81), hypercholesterolaemia (p=0.26), atrial fibrillation (p=1.00) and smoking status (p=0.39) (see table 2). However, there was a significant difference between groups for onset of symptoms (p<0.001) and NIHSS score at admission (p<0.001) and marginally significant difference for serum triglyceride levels (p=0.05). In terms of outcomes, there were no significant differences between the two groups for their mRS score at 90 days (p=0.054), NIHSS score at discharge (p=0.21), mortality at 90 days (p=0.67) and length of stay (p=0.34). Prior stroke and hypertension were the only risk factors that were significantly different between the two groups (p=0.02 and p<0.001, respectively). Table 2Demographic and patient outcomes in patients with lacunar stroke who received thrombolysis and those without thrombolysis using a 1:2 matching processGroupLacunar stroke non-lysisLacunar stroke lysisP valueN475229Age (median, IQR)60.0 (53.0–67.0)60.0 (53.0–67.0)0.84Male sex, n (%)406 (85.5)203 (88.6)0.29Serum HbA1C levels (median, IQR)6.5 (5.6–9.5)6.4 (5.7–8.8)0.58Serum HDL-C (median, IQR)1.0 (0.8–1.2)1.0 (0.8–1.1)0.64Serum LDL-C (median, IQR)3.2 (2.4–4.0)3.2 (2.5–3.9)0.92Serum triglyceride levels (median, IQR)1.5 (1.1–2.2)1.7 (1.2–2.3)0.05Onset of symptoms<0.001 <1.5 hours14 (3.4)83 (36.7) 1.5–3 hours37 (9.0)104 (46.0) 3–4.5 hours37 (9.0)37 (16.4) >4.5 hours323 (78.6)2 (0.9)mRS at 90 days0.054 0–2, n (%)246 (69.9)114 (61.3) 3–6, n (%)106 (30.1)72 (38.7)NIHSS score at admission<0.001 0–4181 (38.1)56 (24.5) 5–10249 (52.4)157 (68.6) >1045 (9.5)16 (7.0)NIHSS score at discharge0.21 0–4134 (52.1)119 (58.9) 5–1094 (36.6)58 (28.7) >1029 (11.3)25 (12.4)Mortality at 90 days, n (%)0.67 Yes, n (%)5 (1.4)1 (0.5) No, n (%)347 (98.6)186 (99.5)Risk factors Hypertension, n (%)373 (78.5)161 (70.3)0.02 Diabetes, n (%)266 (56.0)126 (55.0)0.81 Hypercholesterolaemia, n (%)211 (45.1)114 (49.8)0.26 Prior stroke, n (%)67 (14.1)9 (3.9)<0.001 Atrial fibrillation, n (%)3 (3.0)1 (1.5)1.00 Smoking, n (%)153 (32.2)66 (28.8)0.39 Length of stay, median (IQR)4.0 (2.0–6.0)4.0 (2.0–5.0)0.34HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale. Demographic and patient outcomes in patients with lacunar stroke who received thrombolysis and those without thrombolysis using a 1:2 matching process HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale. Multivariate analysis for risk factors associated with a higher mRS (3–6) at 90 days in patients with stroke Figure 1 illustrates a multivariate conditional logistic regression model to identify significant independent factors associated with a higher mRS3,6 at 90 days for patients with cortical stroke after receiving rt-PA. Past history of hypertension and diabetes mellitus were significant independent predictors of a higher mRS score at 90 days (adjusted odds ratio (aOR) 2.46, 95% CI 1.51 to 4.02, p<0.001; aOR 1.96, 95% CI 1.26 to 3.07, p=0.003, respectively) post rt-PA. Severe admission NIHSS score (>10) was also identified as an independent predictor (aOR 6.93, 95% CI 3.53 to 13.6, p<0.001). Atrial fibrillation, one of the biggest risk factors for cardioembolic stroke (accounts for approximately 80% of cases), was not identified as a significant predictor of functional outcomes at 90 days post rt-PA (aOR 1.59, 95% CI 0.98 to 2.60, p=0.06). Multivariate conditional logistic regression analysis of the risk factors associated with a higher mRS at 90 days in patients with cortical stroke post rt-TPA. NIHSS, National Institute of Health Stroke Scale; rt-PA, recombinant tissue-type plasminogen activator; SO, symptom onset. Multivariate analysis for risk factors associated with a higher mRS (3–6) at 90 days in patients with lacunar stroke Figure 2 illustrates a multivariate conditional logistic regression model to identify significant independent factors associated with a higher mRS3,6 at 90 days for patients with lacunar stroke post rt-PA. High admission NIHSS score (>10) and symptom onset of greater than 3 hours were identified as significant predictors (aOR 5.96, 95% CI 1.52 to 23.4, p=0.01; aOR 3.45, 95% CI 1.34 to 8.89, p=0.01). Multivariate conditional logistic regression analysis of the risk factors associated with a higher mRS at 90 days in patients with lacunar stroke post rt-TPA. NIHSS, National Institute of Health Stroke Scale; rt-PA, recombinant tissue-type plasminogen activator; SO, symptom onset Discussion Ischaemic strokes account for approximately 85% of strokes, and according to TOAST classification of stroke subtypes, large vessel occlusion (defined as obstruction of proximal vessels, ie, the internal carotid artery, proximal anterior, middle and posterior cerebral arteries, basilar artery and intracranial vertebral artery)16 is comprised mainly of cardioembolic stroke (20–30%), LAA (10–20%) and stroke of undetermined causes.1 2 17 18 Lacunar strokes on the other hand are small cerebral infarctions (2–20 mm in diameter) caused by occlusion of a deep perforated artery.19 Thrombolysis with rt-PA has been used to treat both large vessel occlusions and lacunar strokes, although the efficacy of the latter has been questioned as the implementation of rt-PA increases the risk of haemorrhagic transformation, especially in stroke aetiologies with high frequencies of cerebral microbleeds like lacunar strokes.20 In the present study, we observed that patients with cortical stroke who received rt-PA had a significantly lower proportion of a poor clinical outcome at 90 days (defined as mRS score of 3–6; 41.5% vs 50.5%, p=0.002), significantly lower NIHSS score at discharge (NIHSS score>10: 23.0% vs 33.9%, p<0.001), significantly lower proportion of mortality at 90 days (4.7% vs 8.2%, p=0.02) and significantly lower length of stay at the hospital (5.2 days vs 6.0 days, p=0.01) compared with patients with cortical stroke who did not receive rt-PA. In terms of outcomes for patients with lacunar stroke, there were no significant differences between the two groups for their mRS score at 90 days (p=0.054), NIHSS score at discharge (p=0.21), mortality at 90 days (p=0.67) and length of stay (p=0.34). Multivariate conditional logistic regression model also revealed that high admission NIHSS score (>10) and symptom onset of greater than 3 hours were identified as significant predictors of a poor functional outcome at 90 days (mRS score of 3–6) (aOR 6.93 and 3.45, respectively) for patients with cortical stroke who received rt-PA. History of hypertension and diabetes mellitus were also significant predictors of a poorer clinical outcome at 90 days (aOR 2.46 and 1.96, respectively). Similar predictors were also identified for patients with lacunar stroke who received rt-PA: high admission NIHSS score (>10) (aOR 5.96, 95% CI 1.52 to 23.4, p=0.01) and symptom onset of greater than 3 hours (aOR 3.45, 95% CI 1.34 to 8.89, p=0.01); with the exception of diabetes mellitus and hypertension no longer being significant predictors. Our results on the cortical stroke cohort are consistent with previous studies that have examined the effects of rt-PA in treating large vessel occlusions. Chen et al21 reported that 62/77 patients with LAA had a good outcome after 3 months compared with patients with LAA who did not receive rt-PA (80.5% vs 65.1%, OR 2.19, 95% CI 1.14 to 4.21, p=0.02). In a larger trial of 391 patients, Wang et al22 also reported that patients with LAA who received rt-PA had a significantly higher rate of favourable outcomes at 90 days (82.8% vs 64.9%; OR 2.59, 95% CI 1.13 to 5.02, p=0.024) compared with patients with LAA who did not receive rt-PA. In a recent trial conducted in China, Xiong et al11 reported that patients treated with tenecteplase had a high proportion of good functional outcomes at 90 days (mRS ≤1) compared with patients who received standard medical treatment (33.0% vs 24.2%, relative rate of 1.37, 95% CI 1.04 to 1.81, p=0.03). Mortality rate at 90 days was also lower in patients who received tenecteplase (13.3% vs 13.1%, relative rate of 1.01, 95% CI 0.65 to 1.58) albeit the difference was not statistically significant.11 In contrast, we did not observe a significant difference in functional outcomes, mortality rate and length of stay in the hospital for our patients with lacunar stroke. Our results contribute to the ongoing discussion of whether rt-PA is efficacious in treating lacunar strokes. Several studies have highlighted the benefits of rt-PA in treating lacunar strokes such as improving functional outcomes and reducing hospital stays.23 24 However, these positive results have not been replicated across all studies.8 25 26 A complication of using rt-PA is the potential for haemorrhagic transformation, especially in patients with pre-existing cerebral microbleeds, which are frequent in lacunar infarcts.20 27 Interestingly, we did observe that rt-PA is effective in treating acute ischaemic stroke regardless of stroke subtypes (mRS of 0–2 at 90 days: 58.5% for patients with cortical stroke vs 61.3% for patients with lacunar stroke), consistent with previous findings.9 28 A potential explanation for why rt-PA might not be effective for our patients with lacunar stroke is that our study could have been underpowered compared with previous studies (we only had 229 patients with lacunar stroke who received rt-PA matched with 475 patients with lacunar stroke who did not receive rt-PA). Another rationale is that the infarcts formed in lacunar strokes are from microatheroma and lipohyalinosis processes, which traditionally have not been responsive to rt-PA as they do not form erythrocyte-fibrin thrombi.7,1023 We also observed that high admission NIHSS score (>10) and late onset of symptoms (>3 hours) were independent predictors of a poor functional outcome at 90 days post rt-PA. Indeed, Adams et al29 have reported that a point increase on the NIHSS decreases the likelihood of a favourable outcome at 7 days and 3 months by 24% and 17%, respectively. In 1996, the Stroke Council of the American Heart Association gave a grade A recommendation for the use of rt-PA within a 3-hour window,30 but the effectiveness of rt-PA beyond the 3 hours window has been contested. In a 2014 Cochrane Review, Wardlaw et al5 reported that thrombolysis therapy within 6 hours resulted in greater odds of symptomatic intracranial haemorrhage, early death and death by 3 to 6 months after stroke in contrast to thrombolysis treatment within 3 hours of stroke. This could perhaps explain why patients who presented with a symptom onset of greater than 3 hours are associated with a poorer clinical outcome as the effectiveness of rt-PA might wane beyond this timeline. Our results also showed that diabetes mellitus was a significant predictor of a poor clinical outcome at 90 days for patients with cortical stroke but not patients with lacunar stroke. Indeed diabetes mellitus is a known risk factor for ischaemic stroke, with previous studies reporting delayed and poor recovery of function post-stroke as well as reduced capacity for cortical plasticity.31 In contrast, past studies have shown mixed results regarding the effects of hyperglycaemia on lacunar infarcts. In a randomised-controlled trial of 1375 patients, Uyttenboogaart et al32 reported that a serum glucose of >8 mmol/L within 6 hours post-stroke was associated with increased odds of a favourable outcome in patients with lacunar stroke (aOR 2.70, 95% CI 1.01 to 1.73, p=0.048). However, in a multicentre study comprised of 3020 participants, Palacio et al33 reported that diabetes mellitus was significantly associated with recurrent stroke, recurrent ischaemic stroke, myocardial infarction and death. The authors however did not analyse clinical outcome at 90 days using the mRS scale. In our current study, diabetes mellitus was indeed a strong predictor of adverse outcomes at 90 days (aOR 1.63, 95% CI 0.83 to 3.20, p=0.16), albeit it was non-significant. Perhaps with a large sample size, statistical significance would have been achieved. Future studies with a large sample size on patients with lacunar stroke with concomitant diabetes mellitus are warranted to further clarify this relationship. Hypertension was also a predictor of a worse clinical outcome at 90 days for patients with cortical stroke but not patients with lacunar stroke. In a meta-analysis conducted by Malhotra et al,34 the authors reported that a high mean systolic BP and high maximum systolic BP pre-mechanical and post-mechanical thrombectomy were associated with decreased functional dependence and increased mortality in patients with large vessel occlusions. Similarly, several studies have also observed positive associations between hypertension and poor clinical outcomes post endovascular treatment, mechanical thrombectomy and intravenous thrombolysis.35,37 As for lacunar stroke, its relationship with hypertension and clinical outcomes post rt-PA is less clear. In a study comprised of 113 patients, Altmann et al38 reported that BP differences between patients with lacunar stroke and patients with non-lacunar stroke were not associated with mRS or NIHSS at discharge (p=0.777 and p=0.887). In a multicentre study, Shin et al39 noted that there was a non-linear association between systolic BP and poor outcome for stroke onset within 1–4 hours in patients with acute lacunar stroke . In our data, 82.7% of our patients with lacunar stroke who received alteplase had symptoms onset within 1–3 hours, perhaps explaining the non-significant effect of hypertension on clinical outcomes in this cohort. However, additional research is warranted with larger sample sizes to determine the impact of hypertension on clinical outcomes in patients with lacunar stroke post rt-PA. There are several limitations to our study. First, the study population is comprised mainly of Middle Eastern ethnicity, South Asian and Far Eastern (Asians); therefore, it lacks generalisability. Second, we did not collect data on the door-to-needle time for all participants; therefore, we could not perform statistical analyses. Moreover, 85% of Qatar’s population is comprised of expatriates from lower-middle income countries who are on average significantly younger compared with the local Qatari population. In addition, the majority of these expatriates are male workers; hence, in our study population, there is a younger onset of stroke presentation and male predominance. In addition, 20–22% of our patients with cortical stroke have concomitant atrial fibrillation, which is in line with other studies where atrial fibrillation tends to be around 10–40%. However, it is important to note that this estimate can be higher due to the difficulties associated with detecting silent, intermittent atrial fibrillation.40 There are, however, several strengths to this study. This study is the first to examine how stroke subtypes affect rt-PA outcomes in a multi-ethnic population. We also had a comparable sample size for our patients with cortical stroke and patients with lacunar stroke as previous studies.9 11 23 Conclusion Patients with cortical stroke who received rt-PA had a significantly lower proportion of a poor clinical outcome at 90 days, significantly lower NIHSS score at discharge, significantly lower proportion of mortality at 90 days and significantly lower length of stay at the hospital compared with patients with cortical stroke who did not receive rt-PA. In contrast, no significant differences were observed for patients with lacunar stroke who received rt-PA versus controls in terms of their mRS score at 90 days, NIHSS score at discharge, mortality at 90 days and length of stay. Multivariate conditional logistic regression model also revealed that high admission NIHSS score (>10) and symptom onset of greater than 3 hours were identified as significant predictors of a poor functional outcome at 90 days for patients with cortical stroke and patients with lacunar stroke who received rt-PA. Diabetes mellitus and hypertension were also significant predictors of outcomes at 90 days for patients with cortical stroke who received intravenous alteplase but not patients with lacunar stroke. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants. The studies involving humans were approved by the Institutional Review Board of the Medical Research Centre at Hamad Medical Corporation (MRC-01-18-102). Participants gave informed consent to participate in the study before taking part. Provenance and peer review: Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. References Associated Data Data Availability Statement Data are available upon reasonable request.